Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts and Other Receivables, Net, Current Accounts receivable, net Prepaid Expense, Current Prepaid expenses Inventory, Finished Goods, Gross Inventory Other Assets, Current Other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Non-current assets Other Assets, Noncurrent Other non-current assets, net of amortization Assets, Noncurrent Total non-current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Operating Lease, Liability, Current Operating lease liability - current Current operating lease liabilities Contract with Customer, Liability, Current Contract liability - Norgine Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Long-Term Debt, Gross Term loan Interest Payable PIK interest Debt Instrument, Unamortized Discount Less: unamortized debt discount Debt discount Contract with Customer, Liability, Noncurrent Contract liability - long-term Liabilities, Noncurrent Total long term liabilities Liabilities Total liabilities Stockholders' Equity Stockholders' deficit: Common Stock, Value, Issued Common stock, no par value; unlimited shares authorized; 27,329 shares issued and outstanding (2023 27,027) Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Equity, Attributable to Parent Balance Balance Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Common Stock, No Par Value Common stock, no par value Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Statement [Table] Statement [Line Items] Loss per Share Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Pedmark revenue PEDMARK product sales, net Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Licensing revenue, PEDMARK Licensing revenue Revenues Net product revenues Total revenue Operating Expenses [Abstract] Operating expenses: The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Cost of product sales Research and Development Expense Research and development Selling and Marketing Expense Selling and marketing General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Net (loss)/income from operations Nonoperating Income (Expense) [Abstract] Other (expense)/income Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Unrealized foreign exchange (loss)/gain Amortization of Debt Issuance Costs and Discounts Amortization expense Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading). Debt Securities Unrealized Loss Unrealized loss on securities Interest Income (Expense), Operating Interest income Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. Interest expense on debt Interest expense Nonoperating Income (Expense) Total other expense Net Income (Loss) Net (loss)/income from operations Net income/(loss) Earnings Per Share, Basic Basic net (loss)/income per common share Earnings Per Share, Diluted Diluted net (loss)/income per common share Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares, basic Weighted-average number of common shares outstanding basic Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of common shares outstanding diluted Weighted-average common shares, dilutive Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member] Employees Shares, Outstanding Balance (in shares) Balance (in shares) APIC, Share-Based Payment Arrangement, Recognition and Exercise Stock-based compensation Stock Issued During Period, Value, Stock Options Exercised Stock option exercise Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of Options Exercised Exercise of options (in shares) Stock option exercise (in shares) Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock release Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Restricted stock release (in shares) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income/(loss) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amount of amortization expense attributable to Norgine asset. Amortization of Norgine asset Amortization of Debt Discount (Premium) Amortization of debt discount Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Realized gain on available for sale securities Gain on securities Amortization of Debt Issuance Costs Amortization of debt access fees Debt Securities, Available-for-Sale, Unrealized Loss Unrealized loss on securities Amount of paid in kind interest, classified as operating. Payment of PIK interest PIK interest Share-Based Payment Arrangement, Noncash Expense Stock-based compensation - employees Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivables Increase (Decrease) in Prepaid Expenses, Other Prepaid expenses Increase (Decrease) in Inventories Inventory Increase (Decrease) in Other Operating Assets Other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Contract with Customer, Liability Contract liability - Norgine Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Proceeds from Stock Options Exercised Proceeds from issuance of stock options Issuance of shares, options exercise Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. Cash paid for taxes on restricted share release Cash paid for taxes on restricted share release Capital Expenditures Incurred but Not yet Paid Capitalized deferred issuance costs Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Increase/(decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents - End of period Cash and cash equivalents - Beginning of period Nature of Business and Going Concern Nature of Operations [Text Block] Nature of Business and Going Concern Significant Accounting Policies Significant Accounting Policies [Text Block] Significant Accounting Policies Income/(loss) per Share Earnings Per Share [Text Block] Income/(loss) per Share Equity [Text Block] Stockholders' Equity Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Term Loans Debt Disclosure [Text Block] Term Loans License Agreement The entire disclosure for licensing agreements. License Agreement Disclosure [Text Block] License Agreement Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Segment Reporting, Policy [Policy Text Block] Segment and Geographic Information Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Inventory, Policy [Policy Text Block] Inventory Revenue [Policy Text Block] Revenue Recognition Disclosure of accounting policy with regard to license agreements. License Agreement, Policy [Policy Text Block] License Agreements Disclosure of accounting policy for recording or deferring costs in anticipation of future contract sales in a variety of circumstances. The costs may consist of (a) costs incurred in anticipation of a specific contract that will result in no future benefit unless the contract is obtained (such as the costs of mobilization, engineering, architectural, or other services incurred on the basis of commitments or other indications of interest in negotiating a contract), (b) costs incurred for assets to be used in connection with specific anticipated contracts (for example, costs for the purchase of production equipment, materials, or supplies), (c) costs incurred to acquire or produce goods in excess of the amounts required under a contract in anticipation of future orders for the same item, and (d) learning, start-up, or mobilization costs incurred for anticipated but unidentified contracts. Cost to Obtain Contract [Policy Text Block] Cost to Obtain Contract Revenue Recognition for Alternative Revenue Programs, Policy [Policy Text Block] Net Product Revenue Disclosure of accounting policy for product sales discounts and allowances. Product Sales Discounts and Allowances [Policy Text Block] Product Sales Discounts and Allowances Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block] Trade Receivables Cost of Goods and Service [Policy Text Block] Cost of Products Sold Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Fair Value of Financial Instruments, Policy [Policy Text Block] Financial Instruments Marketable Securities, Policy [Policy Text Block] Common Shares and Warrants Research and Development Expense, Policy [Policy Text Block] Research and Development Costs and Investment Tax Credits Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk Income Tax, Policy [Policy Text Block] Income Taxes Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Earnings Per Share, Policy [Policy Text Block] Net Income/(Loss) Per Share Disaggregation of Revenue [Table Text Block] Schedule of PEDMARK Revenues, Net Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of PEDMARK Revenues, Discounts and Allowances Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrants to Purchase Common Stock Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Recognized Expense Related to Employee Option Exercises Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of Share-Based Compensation, Stock Option Activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-Based Compensation, Stock Option Volatility Measurements Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Restricted Share Unit Activity Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis Schedule of Components of Leveraged Lease Investments [Table Text Block] Schedule of components of operating lease liability Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Aggregate Annual Term-Loan Payments Schedule of Long-Term Debt Instruments [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Exclusive Licensing Agreement [Member] Licensing Agreement Counterparty Name [Axis] Counterparty Name [Domain] Norgine LTD. Norgine LTD [Member] Norgine Ltd. Lender Name [Axis] Line of Credit Facility, Lender [Domain] Petrichor Opportunities Fund I LP Petrichor Financing Bridge Bank financing lender. Bridge Bank Debt Instrument [Axis] Debt Instrument, Name [Domain] Contracts that allow the holder to convert outstanding debt issuances to equity units from the entity. Securities Purchase Agreements Information pertaining to the first amendment to contracts that allow the holder to convert outstanding debt issuances to equity units from the entity. Securities Purchase Agreement First Amendment [Member]] SPA First Amendment Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Represents information relating to Bridge bank term loan. Bridge Bank Term Loan Convertible Debt [Member] Secured Convertible Debt First round of borrowing under the Petrichor Securities Purchase Agreement which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. First Closing Note Second round of borrowing under the Petrichor Securities Purchase Agreement which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Second Closing Note Third round of borrowing under the Petrichor Securities Purchase Agreement which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Third Closing Note [Member] Third Closing Note Subsequent rounds of borrowing under the Petrichor Securities Purchase Agreement, where the Company may draw up to $20,000,000 in one or more traches of $10,000,000, which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Subsequent Closing Notes First round of warrant issuances under the Petrichor Securities Purchase Agreement which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. First Closing Warrant Second round of warrant issuances under the Petrichor Securities Purchase Agreement which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Second Closing Warrant Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Debt Instrument [Line Items] Nature of Business and Going Concern [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Debt Instrument, Face Amount Borrowings, face amount Line of Credit Facility, Remaining Borrowing Capacity Remaining borrowing capacity Debt Instrument, Convertible, Conversion Price Initial conversion price Represents the percentage premium over the 5-day volume weighted average conversion price in debt agreement. Premium Over Volume Weighted Average Conversion Price (Percentage) Premium over 5-day VWAP Term in which the volume weighted average price is determined in connection with new financing agreements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Volume Weighted Average Price Term VWAP term Repayments of Bank Debt Repayment of term loan Represents number of tranches of loans. Number of loan tranches for remaining borrowing capacity Represents the percentage commitment fee payable on the notes from the security purchase agreement. Commitment fee percentage Represents the amount of common shares available for purchase with the issuance of warrants in connection with commitment fees payable under the security purchase agreement. Common shares available through issuance of warrants Represents the percentage of the commitment fees payable in the form of cash payment or additional warrant issuances. Percentage of commitment fees payable in cash or warrants Commitment fees payable in cash or warrants Exercise Price Of Warrants Issued during the relevant period Exercise price of warrants issued Issued warrants during period, weighted-average price Term from the grant date in which the holder of warrants has to exercise the option to purchase common shares, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Exercise term of warrants Amount of funding received through license agreements. License agreement funding received Amount of potential milestone funding available through license agreements. License agreement funding, potential milestone payments Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Warrant [Member] Warrants to Purchase Common Shares Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restricted Stock [Member] Restricted Stock Employee Stock Option [Member] Options to Purchase Common Shares Employee Options Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money Market Funds Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Number of Operating Segments Accounts Receivable, Allowance for Credit Loss, Current Allowance for doubtful accounts The company's expectation for the percentage of prompt payment discounts customers will earn. Percentage of prompt payment discounts expected to pay out Cash Cash Cash, FDIC Insured Amount FDIC insured amount Class of Warrant or Right, Outstanding Common shares issuable upon exercise of outstanding warrants, ending balance Common shares issuable upon exercise of outstanding warrants, beginning balance Warrants outstanding Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted-average exercise price, end of period Weighted-average exercise price, beginning of period Warrants exercise price Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from EPS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Represents information pertaining to Processa Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc Product and Service [Axis] Product and Service [Domain] Information relating to PEDMARK. PEDMARK Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Represents the number of shares entitled to receive under license agreement. Collaborative Arrangement, Shares to be Issued Shares to be issued under agreement Shares to be issued under agreement Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Amount of gross revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Gross product revenue Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition. Refunds, discounts and allowances Discounts and allowances Scenario [Axis] Scenario [Domain] Represents information relating to chargebacks, discounts for prompt payment and other allowances related to product sales. Chargebacks, Discounts for Prompt pay and Other allowances Represents information pertaining to rebates, customer fees/credits and co-pay assistance related to product sales discounts and allowances. Rebates, Customer Fees/Credits and Co-pay Assistance Provision for aggregate discounts and allowances provided to customers and offset to gross revenues earned. Provision for discounts and allowances Provision for discounts and allowances, ending balance Provision for discounts and allowances, beginning balance Amount of expense (reversal of expense) for expected discounts and allowances on gross sales. Discounts and allowances, provision for current period sales Current period Payments made against the Company's provision for product sales discounts and allowances. Discounts and allowances, payments and customer credits issued Payments and customer credits issued Manufacturing costs related to PEDMARK and capitalized to inventory. Manufacturing costs capitalized to inventory Manufacturing costs related to PEDMARK and capitalized to inventory, amount classified as raw materials. Manufacturing costs capitalized to inventory, raw materials Manufacturing costs related to PEDMARK and capitalized to inventory, amount classified as work-in-process. Manufacturing costs capitalized to inventory, work-in-process Manufacturing costs related to PEDMARK and capitalized to inventory, amount classified as finished goods. Manufacturing costs capitalized to inventory, finished goods Manufacturing costs related to PEDMARK and capitalized to inventory, amount reclassified as cost.of products sold. Manufacturing costs capitalized to inventory, cost of products sold Numerator [Abstract] Numerator: Denominator [Abstract] Denominator: Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Dilutive effect of stock options Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted share units. Dilutive effect of restricted share units Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Dilutive effect of warrants Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Dilutive effect of convertible debt Weighted Average Number of Shares Outstanding, Diluted, Adjustment Incremental dilutive shares Convertible debt that may be used to purchase common shares. Convertible Debt to Purchase Common Shares [Member] Convertible Debt to Purchase Common Shares Restricted share units to purchase common shares. Restricted Share Units to Purchase Common Shares [Member] Restricted Share Units to Purchase Common Shares Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Represents the warrants exercised during period. Stock Issued During Period Shares Warrants Exercised Exercised warrants during period The number warrants issued by the company during the relevant period. Class Of Warrant Or Right Issued Issued warrants during period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Life (years) Recognized Employee Expense [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Recognized Employee Expense [Line Items] Stock or Unit Option Plan Expense Total option expense recognized Fair Value, by Balance Sheet Grouping [Table] Award Type [Axis] All Award Types Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Options Outstanding at Ending Number of Options Outstanding at Beginning Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Number of Options Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of Options Forfeited Number of stock options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-average Exercise Price Outstanding at Ending Weighted-average Exercise Price outstanding at Beginning Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average Exercise Price Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-average Exercise Price Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-average Exercise Price Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Number of options fully vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life Plan Name [Axis] Plan Name [Domain] Represents information pertaining to Equity Incentive Plan. Equity Incentive Plan Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] US Denominated RSU's Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested RSUs, end of period Unvested RSUs, beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) RSU's awarded The number of equity-based payment instruments, excluding stock (or unit) options, that were released during the reporting period. Released RSU's released Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period RSU's forfeited Stockholders Equity Note [Table] Stockholders Equity Note [Table] Stockholders Equity Note [Line Items] Stockholders Equity Note [Line Items] Percentage of Common Shares Outstanding Percentage Of Common Shares Outstanding Shares issuable under Stock Option Plan, as percent of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares issuable under Stock Option Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Expiration term Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Price in Active Markets for Identical Instruments Level 1 Money Market Accounts Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs Level 2 Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Common Stock, Value, Outstanding Processa common shares Fair Value, Assets and Liabilities Measured on Recurring Basis [Table] Fair Value Assets and Liabilities Measured On Recurring Basis [Table] Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] Fair Value Assets and Liabilities Measured On Recurring Basis [Line Items] Other Commitments [Axis] Other Commitments [Domain] Information relating to the Company's exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including PEDMARK and their use in oncology (the " OHSU Agreement"). Oregon Health & Science University Agreement Information relating to the Company's lease contingencies. Lease Contingencies Information relating to ongoing litigation with CIPLA Ltd. and CIPLA USA over their submission to the FDA for a generic version of the Company's trademarked medication, PEDMARK. CIPLA ANDA Litigation Represents information related to executive severance payments. Executive Severance Title and Position [Axis] Title and Position [Domain] Chief Executive Officer [Member] Rostislav Raykov, CEO Robert Andrade Geographical [Axis] Geographical [Domain] Represents information pertaining to leases in Triangle Park, North Carolina. Triangle Park, North Carolina Represents information pertaining to leases in Hoboken, New Jersey. Hoboken, New Jersey IRELAND Dublin, Ireland Represents information pertaining to the Company's Office Service Agreement with Regus to lease office space. Office Service Agreement Represents information pertaining to the Company's second Office Service Agreement with Regus to lease office space. Second Office Service Agreement [Member] Second Office Service Agreement Licensing term under OHSU agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Licensing term OHSU agreement Days notice required to terminate OHSU agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Days Notice To Terminate OHSU Agreement Days notice required to terminate OHSU agreement Days notice required by Fennec to terminate OHSU agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Days Notice Required By Fennec To Terminate OHSU Agreement Days notice required by Fennec to terminate OHSU agreement Royalty Expense Accrued royalty expenses Operating Lease, Expense Monthly lease expense Days notice required to terminate lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Operating lease, days notice required to terminate agreement Amount of operating lease penalties and contingent payments due. Operating lease, penalties and contingent payments payable Security Deposit Liability Security deposit The variable rate of interest (added to the current prime interest rate) used in determining the Company's incremental borrowing rate. Variable Interest Rate Over Prime Variable rate over prime Days following the receipt of a Notice Letter in which the Company can formally file a patent infringement suit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Days following receipt of Notice Letter to file patent infringement suit Duration of FDA's ability to give final approval to proposed products that reference PEDMARK subsequent to the filing of a patent infringement suit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Duration of FDA's ability to give final approval to proposed products that reference PEDMARK Duration of PEDMARK's exclusivity period due to Orphan Drug Exclusivity status, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. PEDMARK's Orphan Drug Exclusivity period Duration of PEDMARK's exclusivity period under the European Market Exclusivity for Pediatric Use (PUMA) program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. PEDMARK's exclusivity period under PUMA Registration Payment Arrangement, Maximum Potential Consideration Severance payments due Represents number of severance payments following executive's termination. Number of severance payments Term over which severance payments will be made in the event of employment termination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Term of executive severance in event of termination Severance payment term Lessee, Operating Lease, Term of Contract Remaining lease terms (in months) Lessee, Operating Lease, Discount Rate Discount rate Lessee, Operating Lease, Liability, to be Paid, Year One 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Amount of lessee's undiscounted obligation for lease payment for operating lease before imputed interest. lease liabilities to be paid before imputed interest imputed interest on amount of lessee's undiscounted obligation. lease liabilities imputed interest Lessee, Operating Lease, Liability, to be Paid Total lease liabilities Operating Lease, Liability Total lease liabilities Debt Issuance Costs, Net Debt issuance costs Warrants and Rights Outstanding Fair value warrants Rate, added to the Prime interest rate, at which cash interest will accrue on outstanding principal. Cash interest accrual rate over Prime Rate at which cash interest will accrue on outstanding principal. Cash interest accrual rate Annual rate for which payment in kind (PIK) interest accrues beginning on the funding date and through August 24, 2024. Accrual rate, PIK interest Interest payable other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. Accrued Paid-in-Kind Interest Long-Term Debt, Fiscal Year Maturity [Abstract] Long-Term Debt, Maturity, Year Four 2027 Payments for accrued in-kind interest. Payment of in-kind interest Payment in kind interest Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Debt instrument, total future payments due Total future payments Long-Term Debt Total term loan, net of discount Amount of incremental costs paid as a part of the Company's license agreement. Incremental costs paid Amount of incremental costs capitalized to other non-current assets as a part of the Company's license agreement. Incremental costs capitalized to other non-current assets